Abstract
The 7-valent pneumococcal conjugate vaccine (PCV-7) has proved to be highly effective against invasive pneumococcal disease and has also provided some protection against all-cause pneumonia and acute otitis media. The objective of this study was to evaluate the projected health benefits, costs and cost-effectiveness of vaccination with the 7-valent conjugated pneumococcal vaccine compared with no vaccination, in all infants in Sweden, taking herd immunity into account. A Markov model was used and a hypothetical birth cohort was simulated for a lifelong perspective. The results show that vaccination of 1 cohort could potentially prevent 9 cases of pneumococcal meningitis, 22 cases of pneumococcal septicaemia, 509 cases of hospitalized pneumonia, 7812 cases of acute otitis media, and 2.7 fatalities, among children 0-4 y of age and 6 episodes of pneumococcal meningitis and 167 cases of pneumococcal septicaemia among adults. The incremental cost per QALY and LY gained was estimated to Euro 29,200 and Euro 51,400, respectively. When herd immunity was accounted for, the cost per QALYand LY gained was estimated to Euro 5500 and Euro 6600, respectively. Thus, the health benefits of a national vaccination programmeme can be achieved wit...Continue Reading
References
Mar 1, 1981·Reviews of Infectious Diseases·J O Klein
Feb 25, 1999·Epidemiology and Infection·V P Joki-ErkkiläJ Pukander
Jan 5, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W P HausdorffG R Siber
Apr 5, 2000·The Pediatric Infectious Disease Journal·S BlackK Edwards
Oct 13, 2000·Journal of General Internal Medicine·J A BrandenburgM J Fine
Feb 15, 2001·The New England Journal of Medicine·J EskolaUNKNOWN Finnish Otitis Media Study Group
Oct 24, 2001·Scandinavian Journal of Infectious Diseases·M S DahlA Rosengren
Feb 20, 2002·International Journal of Pediatric Otorhinolaryngology·Flemming S VassbotnPer Moller
Sep 28, 2002·The Pediatric Infectious Disease Journal·Steven B BlackJill Hackell
May 2, 2003·The New England Journal of Medicine·Cynthia G WhitneyUNKNOWN Active Bacterial Core Surveillance of the Emerging Infections Program Network
May 7, 2003·The Annals of Otology, Rhinology, and Laryngology·Jacob SadéDavid Cohen
May 15, 2003·Vaccine·E David G McIntoshAdam Lloyd
Sep 30, 2003·Scandinavian Journal of Infectious Diseases·Jonas HedlundGöran Kronvall
Nov 5, 2003·International Journal of Pediatric Otorhinolaryngology·M StraetemansT Kilpi
Jul 24, 2004·BMJ : British Medical Journal·Michael D Rawlins, Anthony J Culyer
Nov 26, 2005·Scandinavian Journal of Infectious Diseases·Heini SaloTerhi Kilpi
Jun 1, 2006·Vaccine·Torbjørn WisløffIvar Sønbø Kristiansen
Aug 31, 2006·The Pediatric Infectious Disease Journal·John HansenJanelle Lee
Oct 31, 2006·Lancet·Cynthia G WhitneyAnne Schuchat
Jan 9, 2007·Vaccine·Philippe BeutelsPierre Van Damme
Apr 10, 2007·Lancet·Carlos G GrijalvaMarie R Griffin
Citations
Apr 5, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Yoko IbukaAlison P Galvani
May 17, 2011·BMC Medicine·Nathorn ChaiyakunaprukPhilippe Beutels
May 6, 2011·Journal of Multidisciplinary Healthcare·Anouk SpeetsCristina Cardoso
Jun 29, 2013·Vaccine·Fernando De la Hoz-RestrepoNelson Alvis-Guzman
Apr 17, 2013·Vaccine·Wantanee KulpengYot Teerawattananon
Jan 31, 2012·Clinical Therapeutics·Asa BySven-Arne Silfverdal
Feb 15, 2015·Vaccine·David Bin-Chia WuPhilippe Beutels
Aug 21, 2015·Emerging Infectious Diseases·Matthew R Moore, Cynthia G Whitney
Jun 16, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Scott D GrosseDavid Feeny
Sep 25, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Richard PitmanUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Jan 17, 2009·Vaccine·Sven Arne SilfverdalIiro Jokinen
Jan 25, 2011·Scandinavian Journal of Public Health·Anouk M SpeetsPatrik A Sobocki
Sep 20, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Richard PitmanUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Nov 30, 2013·PharmacoEconomics·Katelijne van de VoorenLivio Garattini
Jan 22, 2011·PharmacoEconomics·Chantal W B BoonackerMaroeska M Rovers
Apr 11, 2012·Cadernos de saúde pública·Bianca Rezende LucarevschiSandra Grisi
Oct 24, 2018·Applied Health Economics and Health Policy·Tara A LavellePei-Jung Lin
Nov 9, 2017·Human Vaccines & Immunotherapeutics·Xu-Hao ZhangChul-Min Kim
Mar 2, 2017·PloS One·Marisa HolubarDespina Contopoulos-Ioannidis